Haisco Pharmaceutical Group Co., Ltd. (hereinafter referred to as “Haisco” or the “Company”) was established in 2000. It is a diversified, professional pharmaceutical group listed company integrating R&D, manufacturing and sales of new drugs. The Company’s R&D strength ranks among the top in the chemical pharmaceutical industry, its market share in the parenteral nutrition segment is among the top, and it is the fifth largest manufacturer of drugs for liver disease in China, occupying an important position in the two subdivision markets of liver disease, digestion and anti-infection. There are more than 4,000 employees currently, including 50 PhDs and 360 Masters.
The Company listed A-shares on the Shenzhen Stock Exchange on January 17, 2012, and achieved sales of RMB 3.330 billion and net profit of RMB 637 million in 2020.
Haisco has strong technical strength, the R&D center has various scientific research personnel who are more than 700 in total, including numbers of PhDs and Masters. Currently, the R&D center has initiated 65 new projects in the specialized fields of innovative drugs and high-end generic drugs, involving multiple disease fields such as anesthesia and analgesia, diabetes mellitus and complications, tumor, neuralgia, parenteral nutrition, cardio-cerebrovascular, digestive and respiratory diseases. Currently, there are a total of nine Category 1 new drugs under development. Ciprofol Injection, a Category 1 innovative drug, which is the first brand-new intravenous anesthetic drug developed by the Company independently with independent intellectual property rights in China, was successfully marketed during the reporting period. The first approved indication was sedation in gastrointestinal endoscopy, and the indication for induction of general anesthesia was also approved in February 2021, marking exciting results in the Company’s innovative drug research.
The R&D Center owns the independent generic drug research building, the innovative drug research building and the intermediate experiment base, equipped with advanced and precise scientific research instruments, and the test conditions are at the leading level in China. Since its establishment in 2000, 66 varieties have been successfully developed, of which 21 have been marketed as the first generic drug, and the rate of marketed first generic drug exceeds 30%.
The Company currently sells 46 varieties, most of which are the first or exclusive generic products in China, mainly including such as Polyene Phosphatidylcholine Injection, Fat-soluble Vitamin for Injection series, Dorasetron Mesylate Injection, Nalmefene Hydrochloride Injection, Flupentixol and Melitracen Tablets, Cefoperazone Sodium and Tazobactam Sodium for Injection, involving liver disease, parenteral nutrition, depression, and antibiotics fields, etc.
Haisco has a sound sales network and mature marketing channels. According to the guidelines of “Self-building team, Collaborative operation”, the Company has built a huge sales network covering major provinces and cities in China. Guided by the policy of “Medical-driven, Academic-led and Sales-landing”, we adopt a diversified marketing model, innovate pilot projects, and promote work in all areas by drawing upon the experience gained on key points, transform to refinement, systematization, and platformization. At present, our Company has over 1,000 sales personnel and nearly 5,000 management representatives, covering more than 10,000 Grade II and above hospitals.